Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A phase 3 trial testing INCB123667 in ovarian cancer, now recruiting.
Overview
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression is a phase 3 interventional study registered as NCT07214779, led by Incyte with ENGOT Foundation and GOG Foundation, and recruiting when checked on 2026-09-11. Official title: A Phase 3, Randomised, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression. Planned enrolment is 466 participants (estimated). The study started in 2025-12-09 and primary completion is expected in 2028-11-15. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Shares Incyte and the tag ctgov-ingest.
- TrialA Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Shares Incyte and the tag ctgov-ingest.
- TrialA Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialOregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialStudy of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialSHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Shares Ovarian cancer and the tag ctgov-ingest.